In an effort to provide you with timely market feedback from the 2016 ASCO Annual Meeting, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ conducted immediately after the meeting. This report explores genitourinary (non-prostate) presentations concerning the use of checkpoint inhibitors as therapy for bladder cancer and new overall survival data for agents in kidney cancer.
Conclusions: Immediate Impact of 2016 ASCO Presentations on Clinical Practice for Bladder and Kidney Cancer
For a more detailed analysis report, please click here to download the full report.
Submitted by Robert Stephan, VP, Research and Physician Society, and Jan Heybroek, President MDoutlook.
You must be logged in to post a comment